Castleman’s Disease Presenting as Mesenteric Tumour

International Journal of Medical Science

© 2019 by SSRG - IJMS Journal

Volume 6 Issue 6

Year of Publication : 2019

Authors : Md Imran Nasir, Sanjay Gupta,Ranjeev Bhagat, Ashok Kumar Attri

10.14445/23939117/IJMS-V6I6P101

How to Cite?

Md Imran Nasir, Sanjay Gupta,Ranjeev Bhagat, Ashok Kumar Attri, "Castleman’s Disease Presenting as Mesenteric Tumour," SSRG International Journal of Medical Science, vol. 6,  no. 6, pp. 1-3, 2019. Crossref, https://doi.org/10.14445/23939117/IJMS-V6I6P101

Abstract:

Castleman’s disease (akaangiofollicular lymph node hyperplasia) is a rare disorder characterised by enlargement of lymph node.The common sites include lymph nodes of mediastinum, lung, neck, axilla, pelvis and retroperitoneum, but mesenteric Castleman's disease is rarely seen. Patients can be asymptomatic orcan havenon-specific symptoms like fever, night sweats, loss of body weight. Surgical excision of suspicious mass followed by immunohistochemistry of the specimen usually helps in diagnosis. We report the case of a 37 years old lady with abdominal mass which turned out to be Castleman disease of mesentery.

Keywords:

Castleman’sdisease, Mesenteric tumors

References:

[1] Seow-Choen F. The management of desmoids in patients with familial adenomatous polyposis (FAP). Acta Chir 2008; 55:83-7.
[2] Sidhic AK, Ranjith M, Ali KP, Tej PR. Leiomyosarcoma of the mesentery, a rare mesenteric tumour. Int J Surg 2015; 7:58-60.
[3] Goh BK, Chow PK, Kesavan SM. A single-institution experience with eight CD117-positive primary extra-gastrointestinal stromal tumors: critical appraisal and a comparison with their gastrointestinal counterparts. J Gastrointest Surg 2009; 13:1094-8.
[4] Castleman B, Iverson L, Menendez VP. Localized mediastinal lymph node hyperplasia resembling thymoma. Cancer 1956; 9: 822–30.
[5] Metaxas G, Tangalos A, Pappa P. Mucinous cystic neoplasms of the mesentery: a case report and review of the literature. World J Surg Oncol 2009; 7:47.
[6] Bowne WB, Lewis JJ, Filippa DA, Niesvizky R, Brooks AD, Burt ME et al. The management of unicentric and multicentric Castleman’s disease: a report of 16 cases and a review of the literature. Cancer 1999; 85:706-17.
[7] Degot T, Metivier AC, Casnedi S, Chenard MP, Kessler R: Thoracic manifestations of Castleman’s disease. Rev Pneumol Clin 2009; 65:101-7.
[8] Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman's disease: a systematic review of 404 published cases. Ann Surg 2012; 255: 677–84.
[9] Oksenhendler E, Boutboul D, Fajgenbaum D. The full spectrum of Castleman disease: 273 patients studied over 20 years. Br JHaemat 2018;180: 206–16.
[10] Szalat R, Munshi NC. Diagnosis of Castleman Disease. HematolOncol Clin N Am 2018; 32: 53–64.
[11] Fajgenbaum DC, Uldrick TS, Bagg A. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood2017; 129: 1646–57.
[12] Liu AY, Nabel CS, Finkelman BS. Idiopathic multicentric Castleman's disease: a systematic literature review. LancetHaemat 2016; 3: 163–75.
[13] Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2014; 15: 966–74.
[14] Bower M. How I treat HIV-associated multicentric Castleman disease". Blood 2010; 116: 4415–21.